<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655040</url>
  </required_header>
  <id_info>
    <org_study_id>B7981054</org_study_id>
    <nct_id>NCT04655040</nct_id>
  </id_info>
  <brief_title>Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants</brief_title>
  <official_title>A PHASE 1, 2-PERIOD, FIXED-SEQUENCE, MULTIPLE-DOSE, OPEN-LABEL STUDY TO ESTIMATE THE EFFECTS OF RITLECITINIB (PF-06651600) ON THE PHARMACOKINETICS OF A SINGLE DOSE OF CAFFEINE IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a Phase 1, 2 period, fixed sequence, multiple-dose, open-label study of the&#xD;
      effect of ritlecitinib on caffeine PK in healthy participants. Approximately 12 healthy male&#xD;
      and/or female participants will be enrolled in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Actual">March 5, 2021</completion_date>
  <primary_completion_date type="Actual">March 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time profile from time 0 extrapolated to infinity (AUCinf) of caffeine</measure>
    <time_frame>Day1 and Day8: Hour 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24. Day 8: Hour 36 and 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Baseline through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in vital signs</measure>
    <time_frame>Baseline through Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in clinical laboratory values</measure>
    <time_frame>Baseline through Day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Caffeine and Ritlecitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 Day 1, participants will be dosed with a single oral administration of caffeine 100 milligram (mg) tablet.&#xD;
In Period 2 Day 1 to Day 7, participants will be dosed with a single oral administration of ritlecitinib 200 milligram (mg) tablet. On Day 8, participants will be dosed with caffeine 100 milligram (mg) tablet within 5 minutes after administration of a 200 milligram (mg) dose of ritlecitinib on the morning of Day 8. Dosing with oral 200 milligram (mg) ritlecitinib QD will continue until Day 9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>100milligram (mg) tablet taken orally in period 1 and period 2</description>
    <arm_group_label>Caffeine and Ritlecitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ritlecitinib</intervention_name>
    <description>200 milligrams (mg) taken orally once a day(QD) for 8 days</description>
    <arm_group_label>Caffeine and Ritlecitinib</arm_group_label>
    <other_name>PF-06651600</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Male and female participants must be 18 to 55 years of age, inclusive, at the time of&#xD;
        signing the ICD.&#xD;
&#xD;
        -BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb). -&#xD;
&#xD;
          -  Male and female participants who are healthy as determined by medical evaluation&#xD;
             including medical history, physical examination, laboratory tests, and 12-lead ECG.&#xD;
&#xD;
          -  Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria: Participants are excluded from the study if any of the following&#xD;
        criteria apply:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological,&#xD;
             dermatological, or allergic disease (including drug allergies, but excluding&#xD;
             untreated, asymptomatic, seasonal allergies at the time of dosing).&#xD;
&#xD;
          -  History of febrile illness within 5 days prior to the first dose of investigational&#xD;
             product.&#xD;
&#xD;
          -  History of any lymphoproliferative disorder such as EBV related lymphoproliferative&#xD;
             disorder, history of lymphoma, history of leukemia, or signs or symptoms suggestive of&#xD;
             current lymphatic or lymphoid disease.&#xD;
&#xD;
          -  Known presence or a history of malignancy other than a successfully treated or excised&#xD;
             non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in&#xD;
             situ.&#xD;
&#xD;
          -  Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality that may increase the risk&#xD;
             of study participation or, in the investigator's judgment, make the participant&#xD;
             inappropriate for the study.&#xD;
&#xD;
          -  Participants who, according to the information provided on Drugs.com, would be at&#xD;
             increased safety risk if dosed with caffeine.&#xD;
&#xD;
          -  History of hypersensitivity to caffeine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7981054</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

